Basic Campral Information

• INN (International Nonproprietary Name): Metformin is the INN recognized globally, used in pharmaceutical regulation, medical literature, and across drug formularies.

• Brand Names Available In Canada (English): Not specified.

• ATC Code: A10BA02 — A: Alimentary Tract And Metabolism; A10: Drugs Used In Diabetes; A10B: Blood Glucose Lowering Drugs, Excluding Insulins; A10BA: Biguanides; A10BA02: Metformin.

• Forms & Dosages: Tablets (immediate) 500mg, 850mg, 1000mg; Extended-Release Tablets 500mg, 750mg, 1000mg; Oral Solution 500mg/5mL, 100mg/mL; Sachet/Powder 500mg, 1000mg (rare).

• Manufacturers In Canada (English): Not specified.

• Registration Status In Canada (English): Not specified.

• OTC / Rx Classification: Prescription-only (Rx) in most markets; not sold over-the-counter in regulated countries.

Latest Research Highlights

Want to know whether campral helps people stay sober over months and years?

Recent international systematic reviews and meta-analyses (2022–2025) continue to show that acamprosate modestly increases rates of sustained abstinence compared with placebo.

The greatest benefit is seen when medication is combined with psychosocial interventions such as counselling or cognitive behavioural therapy.

Network meta-analyses published in this period compared acamprosate with naltrexone and disulfiram and generally found acamprosate favors abstinence maintenance versus placebo, though effect sizes are small and heterogeneity across studies is common.

Canadian randomised controlled trial data are limited, but cohort analyses from addiction clinics (2020–2024) suggest adherence and retention are the main drivers of real-world effectiveness.

Pragmatic Canadian trials underway (2023–2025) are testing digital adherence supports plus acamprosate to improve outcomes in routine care.

Patient-centred programs in Canada that combine medication with counselling — including services in primary care, addiction medicine clinics, and Indigenous-led programs — report better outcomes than medication alone.

Key 2022–2025 Trials

Data Highlights

• Adherence Predicts Outcome: Real-world audits show that patients who keep follow-up appointments and take acamprosate as prescribed are far more likely to maintain abstinence.

Clinical Effectiveness In Canada

Are medicines like campral approved and commonly used in Canada?

Health Canada has approved acamprosate (Campral and generics) for maintenance of abstinence in alcohol dependence, and provincial guidance across 2019–2024 updates supports medication-assisted treatment as part of care.

Canadian provincial frameworks typically endorse acamprosate as first- or second-line depending on treatment goals such as abstinence versus harm reduction.

Real-world clinic audits from Canadian addiction services show modest effectiveness similar to international randomised trials, with outcomes improving when primary care, pharmacy follow-up and counselling are integrated.

Before prescribing, check product DIN and provincial formulary status such as Ontario Drug Benefit, BC PharmaCare, or RAMQ as many programs require special authority or documentation of an alcohol use disorder diagnosis.

Practical Notes

• Approved Indication: Maintenance of abstinence in detoxified patients with alcohol dependence.

• Off-Label Use: Some clinicians use acamprosate for relapse prevention in heavy-drinking patterns or as adjunctive therapy with psychosocial supports.

• Real-World Effectiveness: Outcomes are best when medication is part of a coordinated package including counselling and pharmacy follow-up.

Indications And Expanded Uses

Who is campral for, and when might providers consider it off-label?

Approved use in Canada is for maintenance of abstinence in patients with alcohol dependence who are already detoxified.

Common off-label uses include relapse prevention for certain heavy-drinking patterns and as an adjunct to psychosocial therapies in stepped-care models.

Emerging trials (2022–2025) examine campral paired with digital behavioural interventions to support adherence, but evidence for harm-reduction-only goals (reducing drinking without full abstinence) remains limited.

Before starting, discuss patient goals clearly — some prefer abstinence while others choose reduction — and use shared decision-making that respects cultural preferences and alternatives.

Assess pregnancy and breastfeeding status and check renal function before initiation, because renal clearance is the main elimination route and affects safety.

Approved Vs Off-Label

• Approved (Canada): Maintenance of abstinence after detoxification.

• Common Off‑Label Uses: Relapse prevention in selected heavy drinkers; adjunct in combination with counselling or digital supports.

Composition And Brand Landscape

What’s inside Campral and how is it sold in Canada?

The active substance is acamprosate calcium (acamprosate INN) and the most common tablet formulation is Campral 333 mg taken orally.

Generics for acamprosate are available in Canada and products carry a Drug Identification Number (DIN) and bilingual labelling as required for the Canadian market.

To illustrate regulatory listing formats, metformin’s INN and ATC breakdown are recorded in regulatory lists as A10BA02, and acamprosate is listed under its INN in its own therapeutic class.

Brand Table

Major Canadian pharmacy chains such as Shoppers Drug Mart, Rexall, Jean Coutu and London Drugs commonly stock Campral or generics, and institutional hospital formularies may list an institutional DIN.

Contraindications And Special Precautions

Who should not take campral and what monitoring is essential?

Primary contraindication is severe renal impairment, and product monographs specify renal cut-offs where acamprosate should not be used.

Do not start acamprosate in patients with acute kidney injury or when estimated GFR is below thresholds in the monograph, since renal clearance predominates and dose adjustment may not be feasible.

Use caution in pregnancy and breastfeeding because safety data are limited, and pregnancy counselling is recommended when applicable.

Adverse event surveillance from 2020–2024 continues to report gastrointestinal side effects such as diarrhoea and rare skin reactions.

Advise temporary discontinuation around procedures or conditions that may reduce renal perfusion, for example major surgery or severe dehydration.

Absolute Versus Relative Contraindications

• Absolute: Severe renal impairment (GFR below product-specified thresholds), hypersensitivity to acamprosate.

• Relative: Pregnancy/breastfeeding (caution), elderly with multimorbidity, unstable medical illnesses affecting renal function.

Dosage Guidelines

What dose do people usually take and how do you adjust for kidney problems?

The standard adult dosing for Campral 333 mg tablets is commonly two tablets (666 mg) three times daily, giving a total of approximately 1998 mg per day.

Some clinicians use a lighter regimen of one tablet three times daily depending on tolerability and patient factors.

Because acamprosate is not significantly metabolised by the liver and is cleared primarily by the kidneys, dose adjustments are required for renal impairment and pediatric use is uncommon.

Geriatric patients need renal monitoring and may require dose modification or avoidance based on eGFR.

Quick Dosage Reference

• Missed Dose: Take as soon as remembered unless it is near the next dose; do not double doses.

• Administration: Take with or without food and maintain a regular schedule to support adherence.

• Practical Counselling: Use pharmacy blistering services or adherence aids to simplify the TID schedule.

Interactions Overview

Will campral interact with my other medicines or alcohol?

Acamprosate has relatively few pharmacokinetic interactions because it is minimally metabolised and is eliminated mainly by the kidneys.

Clinically relevant drug interactions are uncommon, but monitor when co-prescribing drugs that alter renal function such as NSAIDs, ACE inhibitors or aminoglycosides.

Be aware of additive central nervous system effects if acamprosate is taken with sedatives, and counsel that ongoing heavy alcohol use reduces the medication’s effectiveness and can be unsafe.

Health Canada’s product monograph lists interaction advisories and recommended monitoring steps, so consult it when combining with other therapies affecting kidney function.

Interaction Summary

• No Major CYP Interactions: Minimal hepatic metabolism reduces common CYP-mediated interactions.

• Watch For Renal-Impacting Drugs: Adjust monitoring if patient is on nephrotoxic agents.

• Additive CNS Effects: Monitor when co-prescribing benzodiazepines, opioids or other sedatives.

Cultural Perceptions And Patient Habits

How do Canadian patients feel about taking campral?

Qualitative studies in Canada (2020–2024) report mixed perceptions about medication-assisted relapse prevention; some patients welcome a medical tool while others worry about medicalisation.

Online forums and community threads frequently ask about effectiveness and side effects, with diarrhoea commonly mentioned by patients.

Indigenous-led programs emphasize culturally safe, community-driven approaches and often offer medication alongside traditional healing and psychosocial supports.

Rural communities may lack specialist addiction services so pharmacists and primary care providers often play a larger role in initiating and monitoring campral.

Language access matters in Quebec and bilingual services are expected by many patients, and cost or coverage concerns shape expectations in provincial healthcare systems.

Patient Concerns And Enablers

• Concerns: Side effects, medicalisation, and access to counselling.

• Enablers: Pharmacy follow-up, blister packs, combined counselling and culturally adapted care.

Availability And Pricing Patterns

Where can you get campral in Canada and will provincial plans help pay for it?

Campral and generic acamprosate are available in Canada through major pharmacy chains and hospital formularies, though pricing varies between brand and generic options and by province.

Provincial coverage differs; some formularies list acamprosate under addiction services or require special authority and documentation of diagnosis for reimbursement.

In our online pharmacy, campral is available without a prescription, with discreet delivery to Canada (English) in 5-14 days.

Canadians sometimes compare cross-border pricing, but importation rules are restrictive and provincial formularies govern most access pathways.

Pricing And Coverage Table

Practical tip: always provide the pharmacist with the prescriber's documentation and check the DIN to confirm coverage and any special authority requirements.

Comparable Medicines And Preferences

How does campral compare with other medications used for alcohol use disorder?

Main pharmacologic alternatives include naltrexone (oral or injectable), disulfiram and off-label options such as topiramate.

Meta-analyses indicate naltrexone may be more effective at reducing heavy drinking days, while acamprosate better supports continuous abstinence in some studies; choice depends on patient goals and comorbidities.

Renal versus hepatic cautions guide the choice — acamprosate is cleared renally while naltrexone has hepatic considerations — and this influences formulary approvals and prescriber preference in Canada.

Pros And Cons Checklist

• Acamprosate: Pros — supports abstinence, low hepatic burden; Cons — TID dosing, renal precautions, GI side effects.

• Naltrexone: Pros — reduces heavy drinking days, monthly injectable option; Cons — hepatic monitoring needed, opioid contraindication.

• Disulfiram: Pros — deterrent effect when adhered to; Cons — risk with alcohol ingestion, adherence challenges, not suitable for everyone.

FAQ

• Q: How Long Before I See Benefits?

  A: Benefits with campral are usually measured over months and are greatest when combined with counselling and ongoing follow-up, so set realistic timelines with your provider.

• Q: Is Campral Addictive?

  A: No — acamprosate is not addictive and is not a controlled substance.

• Q: Can I Drink While Taking It?

  A: Campral is intended to support abstinence; drinking while taking it reduces effectiveness and may be unsafe, so discuss harm-reduction versus abstinence goals with your prescriber.

• Q: Will Provincial Drug Plans Cover It?

  A: Coverage varies by province; check Ontario Drug Benefit, BC PharmaCare, RAMQ and your local formulary as some programs require special authority or documentation.

Guidelines For Proper Use

What should prescribers and pharmacists do to use campral safely and effectively?

Best-practice guidance recommends acamprosate be used as part of a comprehensive treatment plan that includes a medical assessment, renal function testing, psychosocial support and clear treatment goals.

Confirm the patient is detoxified before starting and obtain baseline renal function to determine suitability and dosing.

Explain the typical dosing schedule (333 mg TID or 666 mg TID for many adults) and plan regular follow-up to monitor adherence and tolerability.

Pharmacists play a central role in medication counselling, offering adherence supports such as blister packs, liaising with prescribers and checking provincial coverage and DINs.

Use telehealth to reach rural patients and adopt culturally safe approaches for Indigenous populations, involving community supports where available.

Delivery Across Canada (English)

Final Notes For Patients

If you or a loved one are considering campral, discuss goals with the prescriber and ask about local counselling resources and Indigenous-led services if culturally appropriate.

Bring a current medication list to your pharmacy so the pharmacist can check renal-interacting drugs and advise on adherence aids like blister packs.

Report persistent diarrhoea, rash, or any signs of kidney trouble such as reduced urine output or swelling to your prescriber promptly.

Ask the pharmacist to verify DIN and provincial coverage before filling to understand potential out-of-pocket costs or special authority requirements.

For people in rural areas, telehealth follow-up and coordinated care with local pharmacies can reduce barriers to successful treatment.